secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001104659-24-086081
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma Q2 2024 revenue $29.1M, up 52% YoY; net loss narrows to $33.6M
----------------------------------------------------------------------------

- Net product revenue $29.1M vs $19.2M in Q2 2023; 74% generated in United States.
- Net loss attributable to common stockholders improved to ($33.6M) or ($0.55)/share from ($46.7M) ($0.82)/share.
- Cash balance $319.1M as of June 30, 2024, up from $275.8M at Dec 31, 2023; runway into 2026.
- Dosed first patients in Japanese cohort for hypothalamic obesity Phase 3 trial; top-line data from pivotal cohort expected 1H 2025.
- Completed sNDA submission to FDA for IMCIVREE in children age 2-6; EC already expanded to age 2 in Europe.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465924086081/0001104659-24-086081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465924086081/tm2420827d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer